Skip to main content
. 2000 Mar 31;2(4):307–310. doi: 10.1186/bcr72

Table 4.

Proportions of BRCA1 and BRCA2 mutations in 117 female breast/ovarian cancer probands, classified by number of cancer patients in the family, age at disease diagnosis, site-specific breast or breast-ovarian/ovarian cancer

Age of proband at disease diagnosis

40 years or less 41-50 years 51 years or more All ages




Cancer patients BRCA1 BRCA2 BRCA1 BRCA2 BRCA1 BRCA2 BRCA1 BRCA2
in family [% (n)] [% (n)] [% (n)] [% (n)] [% (n)] [% (n)] [% (n)] [% (n)]
Breast
One 4 (1/28) 4 (1/28) 0 (0/9)* 0 (0/9)* 0 (0/10)* 0 (0/10)* 2 (1/47)* 2 (1/47)*
Two or three 25 (2/8) 0 (0/8) 0 (0/13) 0 (0/13) 3 (1/34) 9 (3/34) 5 (3/55) 5 (3/55)
Total 8 (3/36) 3 (1/36) 0 (0/22) 0 (0/22) 2 (1/44) 7 (3/44) 4 (4/102) 4 (4/102)
Breast/ovary
None/one 0 (0/1) 0 (0/1) 0 (0/1) 0 (0/1) 0 (0/3) 0 (0/3) 0 (0/5) 0 (0/5)
None to two/ - - 25 (1/4) 0 (0/4) 0 (0/6) 0 (0/6) 10 (1/10) 0 (0/10)
one or two
Total 0 (0/1) 0 (0/1) 20 (1/5) 0 (0/5) 0 (0/9) 0 (0/9) 7 (1/15) 0 (0/15)

Including proband; numbers of BRCA1- and BRCA2-positive cases over number of cases in each age subset are given in parentheses. *The 19 breast cancer patients with no familial clustering of breast/ovarian cancer diagnosed above age 40 years included 10 cases with bilateral breast cancer and nine patients with breast cancer associated with gastrointestinal, pancreatic or endometrial cancer (synchronous/metachronous, four cases; in a first-degree relative, five cases).